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S370 Poster Session II(35.9%) and 8 (20.51%) pts had a HLAmismatched donor. Therapy
associated complications identified included hyperacute GVHD
(13pts [33.3%]), acute renal failure (13 pts [33.3%]), hemolysis (14
pts [35.9%]), neuro-toxicity (7 pts [17.95%]), cytopenias (10 pts
[25.6%]), dyslipidemia (6 pts [15.4%]) and skin changes (2 pts
[5.13%]). 15 pts (38.5%) had GrIII-IV GVHD. 12 pts (30.8%)
died of who 3 (25%) were directly related to the siro-tac associated
toxicity.
Conclusions:We conclude that the sirolimus-tacrolimus combina-
tion GVHD prophylaxis regimen, is associated with considerable
toxicities that contribute to the transplant associated morbidity
and mortality in the allogeneic hematopoietic stem cell transplanta-
tion setting, not attributable to the conditioning regimen. Therefore
this regimen should be used cautiously outside of a clinical trial.
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RESTING REGULATORY T LYMPHOCYTES: A BIOMARKER FOR CHRONIC
GVHD
Parkman, R., Masinsin, B., Mahadeo, K.M., Kapoor, N., Abdel-
Azim, H.M., Shah, A.J. Children’s Hospital Los Angeles, Los Angeles, CA
T cell depletion and peri-transplant serotherapy have reduced the
incidence and severity of acute graft versus host disease (GVHD);
however, chronic GVHD continues to be a major clinical limitation
to the increased use of hematopoietic stem cell transplantation
(HSCT). Deficiencies in naturally occurring regulatory T lympho-
cytes (Treg) have been hypothesized to contribute to chronic
GVHD. The evaluation of the role of Treg lymphocytes in the path-
ogenesis of chronic GVHD have been limited by a lack of well-de-
fined immunophenotypic characterization of Treg lymphocytes.
Most previous evaluations of Treg lymphocytes inHSCT recipients,
which used either CD25 and/or FoxP3 expression, were confounded
by the fact that activated conventional T lymphocytes (Tcon) ex-
pressed CD25 and FoxP3. We have performed a cross-sectional
analysis of pediatric HSCT recipients using theMiyara classification
of Treg lymphocytes. (Immunity 30:899, 2009) The Miyara classifi-
cation can distinguishes between Treg lymphocytes, both resting
and activated, and activated Tcon lymphocytes, permitting a more
accurate assessment of Treg in the HSCT setting. Pediatric
HSCT recipients more than 1 year post-HSCT were evaluated for
their resting (r) and activated (a) Treg lymphocytes and their r/a ratio
determined. (Table 1)
Table 1. Resting and Activated Treg Lymphocytes in HSCT
Recipients
rTreg aTregPatient r/a ratio
(% of total CD4
T lymphocytes x 1021)Allogeneic-
No hx of acute/chronic GVHD 17.3 6.2 4.7
Active chronic GVHD 6.4 1.8 3.5
Hx of chronic GVHD 14.0 6.8 3.2
Autologous 11.3 5.2 2.2
Normal Individuals 19.3 3.6 3.9Allogeneic HSCT recipients with no history of either acute or
chronic GVHD did not differ from normal individuals. Neither
did allogeneic recipients with only a history of acute GVHD nor
the recipients of autologousHSCT. Allogeneic recipients with active
chronic GVHD had reductions in both the percentage of resting
Treg lymphocytes (p 5 .02 compared to normal or recipients with
neither acute nor chronic GVHD) and of activated Treg lympho-
cytes (p 5 .002 compared to recipients without acute or chronic
GVHD and p5 .0008 compared to normals). Allogeneic recipients,
who have had the clinical resolution of their chronic GVHD, did not
differ from normal individuals. The clinical resolution of chronic
GVHD is associated with a normalization of both resting and acti-
vated Treg lymphocytes. The longitudinal evaluation of resting
Treg levels may aid in the management of chronic GVHD patients
and may predict when clinical improvement occurs.452
BORTEZOMIB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE (GVHD)
Wagner, J.L., Mookerjee, B., Filicko-O’Hara, J.E., Grosso, D.A.,
Flomenberg, N. Thomas Jefferson University Kimmel Cancer Center,
Philadelphia, PA
Steroid refractory GVHD remains a significant problem after
allogeneic HSCT with a mortality rate exceeding 90% in some
series and no standard for salvage treatment. Murine data suggest
bortezomib inhibits acute GVHD, but preserves graft-versus-tu-
mor effect. We sought to test whether the same activity could
be demonstrated in a clinical setting. Patients were eligible for
the trial if they had clinical or histological evidence of acute
GVHD and had been treated with 2mg/kg/day of methylprednis-
olone and had 1) either a minimum of 3 days of corticosteroids
with progressive disease or 2) a minimum of 7 days without a re-
sponse or 3) had progression when steroids were tapered to less
than 2mg/kg/day of methylprednisolone. Bortezomib was given
at a dose of 1.3mg/m2 administered as a bolus intravenous injec-
tion twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10
day rest period constituting one 21 day treatment cycle. A com-
plete response (CR) was defined as no clinical or laboratory signs
of acute GVHD in all organs, and a partial response (PR) re-
quired at least a 1 grade reduction in overall GVHD scoring
in at least 1 organ system without worsening in others. Response
was determined on day 21 after the first cycle and every 3 weeks
until 3 months after the last cycle or death whichever came first.
After the 1st cycle, patients achieving CR or PR were treated
with additional cycles until they had a dose limiting toxicity or
a complete response, and patients without response were taken
off study and considered treatment failure. Three of 11 patients
treated were not evaluable for efficacy; 1 withdrew from the
study after less than 1 cycle without signs of toxicity, 1 died 1
week after receiving the 1st cycle of septic shock, and the 3rd pa-
tient developed a concomitant viral infection that could not be
distinguished from possible concomitant GVHD. Of the 8 evalu-
able patients 4 had no response and 4 had at least a partial re-
sponse. In the 4 patients with responses 2 were complete
responses and 2 were partial. Ten of the 11 patients have died,
2 of progressive disease, 6 of infection, 1 of hemorrhage and 1
of pulmonary toxicity. Whether bortezomib contributed to any
of these deaths was unclear. One of the partial responders was
taken off the study for peripheral neuropathy and is still alive
4.5 years later. In this small study bortezomib demonstrated
some activity in steroid refractory acute GVHD with some neu-
rotoxicity.453
LATENT CMV AND THE CD4+ T CELL TRANSCRIPTION PROGRAM IN PA-
TIENTS WITH CHRONIC GVHD
Astigarraga, C.C.1, Tabellini, L.1, Pergam, S.1, Bumgarner, T.1,
Fan, W.1, Grogan, B.1, Storer, B.1, Boeckh, M.1,2, Zaho, L.P.1,
Hansen, J.A.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA
Latent CMV infection is known to have a life long effect on
the distribution of T cell subsets, but little is known about the
impact on cell function. We performed a gene expression analysis
in purified CD4+ T cells from 68 hematopoietic cell transplant
(HCT) recipients (median age 48; range 20-65) studied on aver-
age 5 years after HCT (median 4.75; range 1-20 years). The
study population included 38 patients with active chronic
GVHD (cGVHD) and 30 tolerant (TOL) patients. Tolerance
was defined by absence of signs, symptoms of cGVHD and im-
munosuppressive therapy (IST) for 3 months. Gene expression
was measured on Illumina bead arrays. CMV status was defined
by pre-transplant recipient CMV serology (by ELISA). There
was no recorded evidence of CMV reactivation at the time of
study. Nine of 93 candidate genes associated with immune func-
tion and inflammation were found to be associated CMV seros-
tatus in cGVHD patients at a significance threshold of p\0.05,
but only four genes (ITK; CD86; PLCG1; PIK3CB) were
